Retrospective Analysis for Comparing Efficacy of Axitinib Combined with Different PD-1 Monoclonal Antibody in Treatment of Advanced Renal Cell Carcinoma
Retrospective Analysis for Comparing Efficacy of Axitinib Combined with Different PD-1 Monoclonal Antibody in Treatment of Advanced Renal Cell Carcinoma
OBJECTIVE To compare the efficacy of combined therapy using axitinib with different PD-1 monoclonal antibodies in the treatment of advanced renal cell carcinoma.METHODS Clinical data from patients diagnosed with advanced renal cell carcinoma were collected and divided into three groups according to different regimens:axitinib+toripalimab,axitinib+tislelizumab,and axitinib+sintilimab.Imaging results before and after combined therapy were recorded and evaluated according to RECIST 1.1 criteria.The event free survival(EFS)of each group of patients was calculated with endpoints including disease progression,patient death,discontinuation of medication,and changes in treatment method.Hematologic and biochemical examination including liver function,heart function,kidney function and inflammatory reaction were collected and statistically analyzed for changes before and after the therapy.Statistical significant was defined as P＜0.05.RESULTS After screening,clinical data from 40 patients were collected.The objective response rates(ORR)were 71.43％in the axitinib+toripalimab group,64.29％in the axitinib+tislelizumab group,and 25.00％in the axitinib+sintilimab group.Among them,the ORR of the axitinib+toripalimab group and the axitinib+tislelizumab group was significantly higher than that of the axitinib+sintilimab group(P＜0.05).The disease control rates(DCR)were 82.86％in the axitinib+toripalimab group,100.00％in the axitinib+tislelizumab group,and 91.67％in the axitinib+sintilimab group,with no statistically significant difference among the three groups.The average EFS of the three study groups was(14.6±4.9)months in the axitinib+toripalimab group,(10.1±3.6)months in the axitinib+tislelizumab group,and(9.5±3.2)months in the axitinib+sintilimab group,respectively.Among them,the average EFS of the axitinib+toripalimab group was longer than that of the other two groups,and the difference was statistically significant(P＜0.05).The median EFS was 16.5 months in the axitinib+toripalimab group,9.6 months in the axitinib+tislelizumab group,and 8.8 months in the axitinib+sintilimab group.There were no significant differences in hematologic or biochemical examination results before and after combined therapy,and all results were within the normal reference range.CONCLUSION All three combined therapy regimens could effectively control the progression of advanced renal cell carcinoma.The combination of axitinib with toripalimab showed the best therapeutic effect,followed by axitinib with tislelizumab.The key efficacy results of the axitinib+sintilimab combination were less favorable compared to those of the other two combinations.
维普
万方数据